Neurofilaments in traumatic brain injury – current knowledge
Authors:
L. Fialová
Authors place of work:
Ústav lékařské biochemie a laboratorní diagnostiky, 1. lékařská fakulta, Univerzita Karlova a Všeobecná fakultní nemocnice v Praze
Published in the journal:
Klin. Biochem. Metab., 26, 2018, No. 2, p. 68-75
Summary
Neurofilaments are neurocytoskeletal structures, localized primarily in the axons of neurons. Changes in the neurofilament levels in biological fluids are studied in various neurological disorders. In this review, the findings of studies focused on the determination of individual neurofilament chains in biological fluids in patients with brain injury are presented. Neurofilament levels significantly increase after traumatic brain injury compared to the control groups. Unlike some other biomarkers (such as protein S100b), whose levels reach the highest values within 1 – 2 days after injury, neurofilaments peak after more than one week. The results of studies in patients with severe and mild traumatic brain injuries suggest that neurofilaments could also have prognostic potential.
Based on the encouraging results of previous studies, it appears that serum or cerebrospinal fluid neurofilament determination could be a suitable test which can help to estimate the severity and prognosis of traumatic brain injuries. Determination of serum neurofilaments would complete the examination of existing biomarkers of neurotrauma as well as neuroimaging methods.
Keywords:
neurofilaments – cerebrospinal fluid – serum – traumatic brain injury.
Zdroje
1. Ondrkalová, M., Kalnovičová, T., Štofko, J., Traubner, P., Turčáni, P. Hladiny neurón-špecifickej enolázy pri ložiskovej ischémii mozgu. Klin. Biochem. Metabol., 2006, 14(35), p. 202–206.
2. Matěj, R., Nováková, J., Koukolík, F., Rusina, R. Vyšetřování proteinu 14-3-3 v mozkomíšním moku – klinicko‑patologická korelace. Cesk. Slov. Neurol. N, 2008, 71/104, p. 695-699.
3. Matek, J., Vajtr, D., Krška, Z., et al. Protein S-100b v diferenciální diagnostice komoce mozkové a povrchního poranění hlavy u pacientů v ebrietě. Rozhl. Chir., 2012, 91, p. 545-549.
4. Thelin, E. P., Nelson, D. W., Bellander, B. M. A review of the clinical utility of serum S100B protein levels in the assessment of traumatic brain injury. Acta Neurochir (Wien), 2017, 159, p. 209-225.
5. Pecháň, I. Perspektívy enzymológie cerebrospinálného likvoru. Cesk. Slov. Neurol. N, 1989, 52, p. 11-21.
6. Kelbich, P., Koudelková, M., Machová, H., et al. Význam urgentního vyšetření mozkomíšního moku pro včasnou diagnostiku neuroinfekcí. Klin. mikrobiol. inf. lék., 2007, 13, p. 9-20.
7. Somer, H., Kaste, M., Troupp, H., Konttinen, A. Brain creatine kinase in blood after acute brain injury. J Neurol. Neurosurg. Psychiatry, 1975, 38, p. 572-576.
8. Papa, L., Ramia, M. M., Edwards, D., Johnson, B. D., Slobounov, S. M. Systematic review of clinical studies examining biomarkers of brain injury in athletes after sports-related concussion. J Neurotrauma, 2015, 32, p. 661-673.
9. Němeček, S., Němečková, J., Cerman, J. Patomorfologické poranění mozku. Neurol praxi, 2003, 6, p. 290-295.
10. Petzold, A., Tisdall, M. M., Girbes, A. R., et al. In vivo monitoring of neuronal loss in traumatic brain injury: a microdialysis study. Brain, 2011, 134, p. 464-483.
11. Petzold, A. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol. Sci., 2005, 233, p. 183-198.
12. Liu, Q., Xie, F., Alvarado-Diaz, A., et al. Neurofilamentopathy in neurodegenerative diseases. Open Neurol. J, 2011, 5, p. 58-62.
13. Perrot, R., Eyer, J. Neuronal intermediate filaments and neurodegenerative disorders. Brain Res. Bull., 2009, 80, p. 282-295.
14. Magnoni, S., Esparza, T. J., Conte, V., et al. Tau ele-vations in the brain extracellular space correlate with reduced amyloid-beta levels and predict adverse clinical outcomes after severe traumatic brain injury. Brain, 2012, 135, p. 1268-1280.
15. Hejčl, A., Kelbich, P., Bolcha M., et al. Význam a možnosti vyšetřování metabolismu mozku pomocí mikrodialýzy v neurointenzivní péči. Klin. Biochem. Metabol., 2013, 21(42), p. 13-20.
16. Al Nimer, F., Thelin, E., Nystrom, H., et al. Comparative Assessment of the Prognostic Value of Biomarkers in Traumatic Brain Injury Reveals an Independent Role for Serum Levels of Neurofilament Light. PLoS One, 2015, 10, p. e0132177.
17. Shahim, P., Gren, M., Liman, V., et al. Serum neuro-filament light protein predicts clinical outcome in traumatic brain injury. Sci Rep, 2016, 6, p. 36791.
18. Zetterberg, H., Hietala, M. A., Jonsson, M., et al. Neurochemical aftermath of amateur boxing. Arch. Neurol., 2006, 63, p. 1277-1280.
19. Neselius, S., Brisby, H., Theodorsson, A., et al. CSF-biomarkers in Olympic boxing: diagnosis and effects of repetitive head trauma. PLoS One, 2012, 7, p. e33606.
20. Neselius, S., Brisby, H., Marcusson, J., et al. Neurological assessment and its relationship to CSF biomarkers in amateur boxers. PLoS One, 2014, 9, p. e99870.
21. Shahim, P., Tegner, Y., Gustafsson, B., et al. Neurochemical Aftermath of Repetitive Mild Traumatic Brain Injury. JAMA Neurol., 2016, 73, p. 1308-1315.
22. Zetterberg, H., Jonsson, M., Rasulzada, A., et al. No neurochemical evidence for brain injury caused by heading in soccer. Br J Sports Med., 2007, 41, p. 574-577.
23. Neselius, S., Brisby, H., Granholm, F., Zetterberg, H., Blennow, K. Monitoring concussion in a knocked-out boxer by CSF biomarker analysis. Knee Surg. Sports Traumatol. Arthrosc., 2015, 23, p. 2536-2539.
24. Shahim, P., Zetterberg, H., Tegner, Y., Blennow, K. Serum neurofilament light as a biomarker for mild traumatic brain injury in contact sports. Neurology, 2017, 88, p. 1788-1794.
25. Oliver, J. M., Jones, M. T., Kirk, K. M., et al. Serum Neurofilament Light in American Football Athletes over the Course of a Season. J Neurotrauma, 2016, 33, p. 1784-1789.
26. Siman, R., Toraskar, N., Dang, A., et al. A panel of neuron-enriched proteins as markers for traumatic brain injury in humans. J Neurotrauma, 2009, 26, p. 1867-1877.
27. Vajtr, D., Benada, O., Linzer, P., et al. Immunohistochemistry and serum values of S-100B, glial fibrillary acidic protein, and hyperphosphorylated neurofilaments in brain injuries. Soud. Lek., 2012, 57, p. 7-12.
28. Žurek, J., Baštáková, L., Mihalčin, M., Forbelská, M., Fedora, M. Dynamika neurofilamenta pNF-H jako prediktor mortality u dětí s poraněním mozku. Anest. Intenziv. Med. , 2010, 21, p. 1214-2158.
29. Zurek, J., Bartlova, L., Fedora, M. Hyperphosphorylated neurofilament NF-H as a predictor of mortality after brain injury in children. Brain Inj., 2011, 25, p. 221-226.
30. Shibahashi, K., Doi, T., Tanaka, S., et al. The Serum Phosphorylated Neurofilament Heavy Subunit as a Predictive Marker for Outcome in Adult Patients after Traumatic Brain Injury. J Neurotrauma, 2016, 33, p. 1826-1833.
31. Gatson, J. W., Barillas, J., Hynan, L. S., et al. Detection of neurofilament-H in serum as a diagnostic tool to predict injury severity in patients who have suffered mild traumatic brain injury. J Neurosurg., 2014, 121, p. 1232-1238.
32. Neselius, S., Zetterberg, H., Blennow, K., Marcusson, J., Brisby, H. Increased CSF levels of phosphorylated neurofilament heavy protein following bout in amateur boxers. PLoS One, 2013, 8, p. e81249.
33. Martinez-Morillo, E., Childs, C., Garcia, B. P., et al. Neurofilament medium polypeptide (NFM) protein concentration is increased in CSF and serum samples from patients with brain injury. Clin. Chem. Lab. Med., 2015, 53, p. 1575-1584.
34. Norgren, N., Rosengren, L., Stigbrand, T. Elevated neurofilament levels in neurological diseases. Brain Res., 2003, 987, p. 25-31.
35. Fialova, L., Bartos, A., Svarcova, J., Zimova, D., Kotoucova, J. Serum and cerebrospinal fluid heavy neurofilaments and antibodies against them in early multiple sclerosis. J Neuroimmunol., 2013, 259, p. 81-87.
36. Fialova, L., Bartos, A., Svarcova, J., et al. Serum and cerebrospinal fluid light neurofilaments and antibodies against them in clinically isolated syndrome and multiple sclerosis. J Neuroimmunol., 2013, 262, p. 113-120.
37. Kuhle, J., Barro, C., Andreasson, U., et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin. Chem. Lab. Med., 2016, 54, p. 1655-1661.
Štítky
Clinical biochemistry Nuclear medicine Nutritive therapistČlánok vyšiel v časopise
Clinical Biochemistry and Metabolism
2018 Číslo 2
Najčítanejšie v tomto čísle
- Definition of sepsis and septic shock
- Glycated albumin in blood serum/plasma. Brief overview of the current state.
- Neurofilaments in traumatic brain injury – current knowledge
- Comparison of different electrophoretic systems in the laboratory diagnosis of monoclonal gammopathy